Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: A helmet including a protective head covering, information carrier, adhesive, and flap. The information carrier includes a first panel having a terminal edge, and a second panel having a fold line. The second panel is joined to the first panel to define a pouch having an interior space and an opening to the interior space. The opening is defined by the terminal edge disposed proximately to the first panel below the fold line. The adhesive is configured to affix the first panel to the exterior surface. The flap is pivotally attached to the second panel about the fold line, wherein the second panel is bendable away from the exterior surface at least between the terminal edge and the fold line to enable the flap to pivot about the fold line toward the exterior surface in connection with insertion of the flap into and removal of the flap from the opening.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: A system and method is disclosed for matching service requests from a plurality of users with one provider from a plurality of providers. The system has a plurality of user electronic devices (“UED”), a plurality of provider electronic devices (“PED”), a communications network, a server, and a database. The method has a user process, a provider process, and an intermediating process. The intermediating process takes service requests made from users who are in an Active User Universe and places them on a list of active service requests. The intermediating process allow providers who are in an Active Provider Universe to view list of active service requests. A provider in the Active Provider Universe may select a service request, where upon the intermediating process removes that service request from a list of active service requests.

Abstract: A helmet including a protective head covering, information carrier, adhesive, and flap. The information carrier includes a first panel having a terminal edge, and a second panel having a fold line. The second panel is joined to the first panel to define a pouch having an interior space and an opening to the interior space. The opening is defined by the terminal edge disposed proximately to the first panel below the fold line. The adhesive is configured to affix the first panel to the exterior surface. The flap is pivotally attached to the second panel about the fold line, wherein the second panel is bendable away from the exterior surface at least between the terminal edge and the fold line to enable the flap to pivot about the fold line toward the exterior surface in connection with insertion of the flap into and removal of the flap from the opening.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: A helmet including a protective head covering, information carrier, adhesive, and flap. The information carrier includes a first panel having a terminal edge, and a second panel having a fold line. The second panel is joined to the first panel to define a pouch having an interior space and an opening to the interior space. The opening is defined by the terminal edge disposed proximately to the first panel below the fold line. The adhesive is configured to affix the first panel to the exterior surface. The flap is pivotally attached to the second panel about the fold line, wherein the second panel is bendable away from the exterior surface at least between the terminal edge and the fold line to enable the flap to pivot about the fold line toward the exterior surface in connection with insertion of the flap into and removal of the flap from the opening.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: An information carrier, comprising a pouch having an inwardly-facing first exterior surface and an outwardly-facing second exterior surface, the pouch forming interior space and an 240 opening thereto, adhesive means for affixing the first exterior surface to an object, and a flap pivotally attached to the second exterior surface proximate the opening, for pivoting toward the first exterior surface and insertion into the opening.

Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise Leishmania sterol 24-c-methyltransferase (SMT) polypeptides, portions, variants and/or fusions, as well as polynucleotides encoding SMT polypeptides, portions, variants and/or fusions.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.